Man Group
ABOS icon

Man Group’s Acumen Pharmaceuticals ABOS Stock Holding History

Man Group’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-105,777
Closed -$256K – 1945
2024
Q2 		$256K Sell
105,777
-81,808
-44% -$260K ﹤0.01% 1823
2024
Q1 		$760K Buy
187,585
+42,955
+30% +$162K ﹤0.01% 1642
2023
Q4 		$555K Buy
+144,630
New +$429K ﹤0.01% 1648
2023
Q1 		– Sell
-21,529
Closed -$112K – 1961
2022
Q4 		$116K Buy
+21,529
New +$145K ﹤0.01% 1888

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Man Group's ABOS Position: Q3 2024 in Review

Man Group sold out of Acumen Pharmaceuticals (ABOS) in Q3 2024, closing a stake of 105,777 shares — an estimated $256K sold.

Man Group first reported a position in ABOS in Q4 2022 and held it in 4 quarters. The position peaked at $760K in Q1 2024. 73 funds tracked by Wall St. Rank hold ABOS as of Q3 2024.

  • Man Group reported no remaining Acumen Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Man Group sold 105,777 Acumen Pharmaceuticals shares in Q3 2024, an estimated $256K.
  • Man Group first reported a position in Acumen Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Man Group's Acumen Pharmaceuticals position peaked at $760K in Q1 2024.
  • 73 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2024.

Based on Man Group's 13F filing for Q3 2024, filed 14 Nov 2024.